Stanley Druckenmiller abandoned his chip positions before the market selloff. His fund Duquesne Family Office maintained Natera (NTRA), a cell-free DNA testing group, as its largest holding at 16% in the second quarter, according to an SEC filing. Healthcare remains his top investment bet. Earlier this year, the investor had expressed a desire to diversify his portfolio and reduce the central role of artificial intelligence.
Source: Read the original article
